Novel Radioimmunotherapy Technique Shows Promise in Colorectal Cancer Treatment
A pioneering pretargeted radioimmunotherapy (PRIT) approach has been found effective in eradicating tumors in preclinical models of colorectal cancer, according to recent research published in the Journal of Nuclear Medicine. This innovative method utilizes alpha-emitting radiation to target tumors, thereby minimizing exposure to healthy tissues.
The study highlights the potential of radiopharmaceutical therapies, particularly those involving molecularly targeted alpha-emitting radionuclides. Among these, the 203Pb/212Pb theranostic pair shows significant promise. Despite the recognized toxicity of 212Pb to the kidneys, the PRIT approach is designed to mitigate such effects by directing radiation precisely to tumor sites. This strategy aims to enhance the therapeutic efficacy while minimizing adverse effects on healthy tissues.
Sarah M. Cheal, PhD, assistant professor at Weill Cornell Medicine, and her colleagues developed this new PRIT method by targeting the GPA33 antigen, which is overexpressed in 95% of colorectal cancer tumors. Initial studies involved biodistribution assessments and SPECT/CT imaging with a 203Pb/212Pb-DOTA-based PRIT framework, establishing feasibility and enabling subsequent dosimetry evaluations. The research involved multiple treatment regimens on mice engineered to carry human colorectal cancer tumors.
The findings revealed that administering two consecutive doses, spaced 48 hours apart, resulted in prolonged survival of the mice, with histologic cures observed in three out of five mice in one cohort. Furthermore, this treatment maintained normal bone marrow function and kidney health.
"This PRIT approach delivered effective tumor targeting with minimal toxicity, demonstrating a new therapeutic window for curative radioimmunotherapy," remarked Nai-Kong V. Cheung, MD, PhD, from Memorial Sloan Kettering Cancer Center. He highlighted the acute need for more effective and low-toxicity treatments for advanced colorectal cancer, pointing to this study as an important step toward achieving this goal.
Moreover, the modular nature of this platform allows potential adaptation to various tumor types, broadening its applicability across the oncological spectrum. The results support the emerging role of the 203/212Pb theranostic pair in nuclear medicine and precision oncology.
This research was conducted by a team from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center, including Brett A. Vaughn, Daniela Burnes Vargas, and Shin Seo, among others.